Skip to main content

Published locations for Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and older

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and older

User login

  • Reset your password
  • /content/nilotinib-safe-effective-first-line-therapy-cml-cp-patients-age-65-and-older
  • /hematologynews/article/105269/cml/nilotinib-safe-effective-first-line-therapy-cml-cp-patients-age-65
  • /oncologypractice/article/105269/cml/nilotinib-safe-effective-first-line-therapy-cml-cp-patients-age
  • /hematology-oncology/article/105269/cml/nilotinib-safe-effective-first-line-therapy-cml-cp-patients